Securities code: 300110 securities abbreviation: Huaren Pharmaceutical Co.Ltd(300110) Announcement No.: 2021-072 Huaren Pharmaceutical Co.Ltd(300110)
Announcement on resignation of independent directors and by election of independent directors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Resignation of independent directors
The board of directors of Huaren Pharmaceutical Co.Ltd(300110) (hereinafter referred to as “the company”) recently received a written resignation report from Mr. He Dalin, an independent director of the company. Due to personal work adjustment, Mr. He Dalin plans to work in Xi’an Qujiang culture and finance holding (Group) Co., Ltd. (hereinafter referred to as “Qujiang financial holding”), which is the controlling shareholder of the company, Xi’an Qujiang Tianxu great health investment partnership Parent company of (limited partnership). According to the guidance on the establishment of independent director system in listed companies issued by China Securities Regulatory Commission, in order to ensure the independence of independent directors, Mr. He Dalin applied to resign as an independent director of the seventh board of directors, and resigned as a member of the remuneration and assessment committee, nomination committee and audit Committee of the seventh board of directors. During his tenure, Mr. He Dalin does not hold shares in the company. Mr. He Dalin’s resignation will cause the number of independent directors to be less than one-third of the total number of members of the board of directors. According to the company law, the guidelines for the standardized operation of companies listed on the gem of Shenzhen Stock Exchange, the guidance on the establishment of independent director system in Listed Companies and other relevant provisions, Mr. He Dalin’s resignation will take effect after the new independent director is elected by the general meeting of shareholders of the company. Before that, Mr. He Dalin will continue to perform relevant duties such as independent director and members of the special committee of the board of directors in accordance with relevant laws and regulations and the articles of Association.
During his tenure as an independent director and a member of the special committee of the board of directors, Mr. He Dalin fulfilled his duties and duties diligently, and played a positive role in the standardized operation and healthy development of the company. The board of directors of the company expressed heartfelt thanks to Mr. He Dalin for his contribution to the development of the company!
2、 By election of independent directors
On December 24, 2021, The company held the 10th (Interim) meeting of the 7th board of directors, deliberated and passed the proposal on by election of independent directors of the 7th board of directors. After being nominated by Xi’an Qujiang Tianshu health investment partnership (limited partnership) and reviewed by the nomination committee of the board of directors, the board of directors agreed to by elect Mr. Liu Yong as the candidate for independent directors of the 7th board of directors of the company (see the appendix for the resume of Mr. Liu Yong) and submit it to the first extraordinary general meeting of shareholders in 2022 for deliberation.
As of the date of this announcement, Mr. Liu Yong has not obtained the qualification certificate of independent director, but has made a written commitment to participate in the latest independent director training and obtain the qualification certificate of independent director recognized by Shenzhen Stock Exchange. The qualification and independence of his independent director candidate shall be reviewed by Shenzhen Stock exchange before the general meeting of shareholders can vote.
After the by election of Mr. Liu Yong as an independent director of the company, the total number of directors concurrently serving as senior managers and employees’ representatives in the board of directors of the company does not exceed half of the total number of directors of the company.
After being elected as an independent director by the general meeting of shareholders of the company, Mr. Liu Yong will also serve as a member of the remuneration and assessment committee, nomination committee and Audit Committee of the seventh board of directors. His remuneration is consistent with that of other independent directors. His term of office starts from the date of adoption of the general meeting of shareholders to the expiration of the term of office of the seventh board of directors.
It is hereby announced.
Resume of independent director candidates of the board of directors on December 24, 2001
Mr. Liu Yong, born in September 1955, is a member of the Communist Party of China and a doctor of medicine. He has successively served as lecturer and associate professor of School of basic medicine of Xi’an Jiaotong University. He is now a researcher, professor and director of the Institute of neurobiology, School of basic medicine, Xi’an Jiaotong University, and enjoys the special allowance of the State Council.
Mr. Liu Yong does not hold the company’s shares and has no relationship with the actual controller of the company, other shareholders holding more than 5% of the company’s shares, other directors, supervisors and senior managers. Mr. Liu Yong has not been punished by China Securities Regulatory Commission and other relevant departments and the stock exchange. There is no situation that he is not allowed to serve as a director of the company as stipulated in the company law and the articles of association, and there is no article 3.2 of the guidelines for the standardized operation of companies listed on the gem of Shenzhen Stock Exchange The circumstances specified in Article 4 are not the person subjected to execution in breach of faith.
